Search

everythinglearnresearchcommunity

for

Search:↓

Scalp tension potentially affecting hair loss, and potential treatments for male pattern baldness such as Minoxidil, Finasteride and RU58841. Evidence from a study was discussed which suggests that the cause of MPB lies within the follicle itself and is not dependent on its surrounding environment.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

RU58841 is being considered for hair maintenance by someone who can't tolerate finasteride. Alternatives like topical finasteride, dutasteride, and KX826 are also suggested.

PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.

Pyrilutamide shows promising hair growth results, but skepticism exists due to potential biases and lack of blinding in the study. Concerns about side effects and legitimacy of the product persist, with comparisons to finasteride and discussions on post-finasteride syndrome.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.

NAD⁺ precursors and EGCG may increase hair density, but users report mixed results with no significant hair gains. Some users suggest combining these with finasteride or dutasteride for better results.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

User tried Pyrilutamide for hair loss and noticed less hair fall initially, but experienced more hair fall after four days. Others advised to assess results after a longer period and consider increasing dosage for better results.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

A user is seeking recommendations for purchasing Minichek 5% solution, a PG-free minoxidil, due to a contact allergy to propylene glycol. They are looking for an affordable option comparable in price to Kirkland or Amazon brand minoxidil.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

Lactobacillus reuteri 6475 is being used by a person who reports healthier hair after one month, despite initial shedding. The discussion includes speculation about its effects on gut bacteria and scalp inflammation.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.

The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.

The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.

RU58841's potential toxicity to cats is uncertain, similar to minoxidil. Caution is advised to prevent accidental exposure to pets.

The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.

Microneedling combined with latanoprost may convert vellus hairs to transitional or terminal hairs. The user suggests using oral minoxidil to increase vellus hair, then applying a high concentration of latanoprost with microneedling for conversion.

A user experienced high estrogen levels after 10 months of taking 1mg oral finasteride but is happy with hair regrowth. They are considering switching to topical finasteride and are also taking DIM and Zinc supplements.

Bimatoprost and latanoprost are being considered for scalp hair growth, with concerns about side effects like skin darkening and fat loss. A user warns about potential chemical burns from latanoprost.

A user seeks advice on mixing RU58841 serum using European ingredients, specifically struggling to find propylene glycol. They are looking for alternatives to American products commonly recommended in guides.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

Minoxidilmax offering a 0.5% Pyrilutamide solution and debating the cost, effectiveness, and safety of using it alone or with other treatments such as Finasteride and Minoxidil.

Vitamin D deficiency can hinder hair recovery, and addressing it may help with hair loss. Hair loss may result from various issues like excess DHT, vitamin deficiency, or scalp inflammation.

The conversation discusses hair thinning potentially linked to gut health issues and suggests biotin as a possible treatment. It also mentions that hair thinning could be due to male pattern baldness (MPB).

GHK-Cu serums for hair growth have mixed results, with some users not seeing significant benefits. Users have tried various brands like Tricomin and Actifolic without success.

Triple Hair's TH-16, a product claimed to be more effective than Minoxidil 5%, has been released; it contains melatonin and resveratrol. One user reported success with topical melatonin and dermarolling.

Pyrilutamide is discussed as an effective hair loss treatment by some users, despite skepticism due to limited data and underwhelming trial results. Users compare it to finasteride, minoxidil, and RU58841, with some expressing interest in its potential as an adjunct treatment.